Emmaus Life Sciences Reports Q3 2023 Financial ResultsNovember 14, 2023
Emmaus Life Sciences, Inc., today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2023.
Read MoreEmmaus Life Sciences, Inc., today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2023.
Read MoreEmmaus today reported that on August 18, 2023, the Board of Directors, including Yutaka Niihara, M.D., Ph.D, determined that Dr. Niihara would no longer serve as Chief Executive Officer of Emmaus, or as Chairman of the Board.
Read MoreEmmaus Life Sciences, Inc. today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2023.
Read MoreEmmaus today announced that it has received marketing authorization from the Oman Ministry of Health for the commercial distribution and sale of Endari®
Read MoreEmmaus has received a Medicine Registration Certificate (DRN-10164/23) from the Bahrain National Health Regulatory Authority (NHRA) granting marketing authorization for the commercial distribution and sale of Endari® in the Kingdom of Bahrain.
Read More